Literature DB >> 12687289

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.

Kiyoshi Mori1, Tetsuro Kondo, Yukari Kamiyama, Yasuhiko Kano, Keigo Tominaga.   

Abstract

PURPOSE: Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a beta-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea.
METHODS: Of 44 previously untreated patients with advanced non-small-cell lung cancer randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation. The chemotherapy regimen consisted of a combination of cisplatin and CPT-11. TJ-14 (7.5 g/day) was administered orally.
RESULTS: Of the 41 patients, 39 experienced diarrhea. Compared with the control group, the TJ-14 group showed a significant improvement in diarrhea grades ( P=0.044) as well as a reduced frequency of diarrhea grades 3 and 4 (one patient versus ten patients; P=0.018). However, the two groups showed no differences in the frequency of diarrhea or the number of days the symptoms continued. This study was stopped at an interim evaluation.
CONCLUSION: TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687289     DOI: 10.1007/s00280-003-0585-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  48 in total

Review 1.  Complementary alternative medicine and nuclear medicine.

Authors:  Ursula Werneke; V Ralph McCready
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 2.  Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

Authors:  Vicente Valentí Moreno; Joan Brunet Vidal; Hermini Manzano Alemany; Antonia Salud Salvia; Montserrat Llobera Serentill; Inés Cabezas Montero; Sonia Servitja Tormo; Eugenia Sopena Bert; Josep Gumà Padró
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

Review 3.  Japanese herbal medicine in functional gastrointestinal disorders.

Authors:  H Suzuki; J M Inadomi; T Hibi
Journal:  Neurogastroenterol Motil       Date:  2009-03-25       Impact factor: 3.598

4.  Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Authors:  Akira Takakura; Akinobu Kurita; Takashi Asahara; Masanori Yokoba; Michiko Yamamoto; Shinichiro Ryuge; Satoshi Igawa; Yukitoshi Yasuzawa; Jiichiro Sasaki; Hirosuke Kobayashi; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2011-12-09       Impact factor: 2.967

5.  Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines.

Authors:  Takashi Takeda; Takuhiro Yamaguchi; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2011-06-25       Impact factor: 3.402

6.  Patient-centered care in lung cancer: exploring the next milestones.

Authors:  Eran Ben-Arye; Noah Samuels
Journal:  Transl Lung Cancer Res       Date:  2015-10

7.  Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo.

Authors:  Xiao-Fang Xu; Bo-Lei Cai; Su-Min Guan; Yan Li; Jun-Zheng Wu; Yong Wang; Bin Liu
Journal:  Invest New Drugs       Date:  2010-03-06       Impact factor: 3.850

Review 8.  Microbiota as a mediator of cancer progression and therapy.

Authors:  Jillian L Pope; Sarah Tomkovich; Ye Yang; Christian Jobin
Journal:  Transl Res       Date:  2016-08-03       Impact factor: 7.012

9.  Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.

Authors:  Satoshi Yuuki; Yoshito Komatsu; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Masao Watanabe; Miki Tateyama; Yasuyuki Kunieda; Osamu Wakahama; Yu Sakata; Masahiro Asaka
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 10.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.